Progenics pharmaceuticals inc (PGNX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-66,618

-68,552

-71,981

-77,496

-72,968

-67,657

-55,618

-46,613

-48,077

-51,013

-55,567

-3,933

7,046

10,733

10,798

-35,498

-41,538

-39,119

-44,144

2,845

3,469

4,410

8,038

-39,437

-40,627

-42,572

-34,345

-35,146

-33,603

-35,431

-45,853

-45,984

20,222

10,381

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

4,193

4,392

4,195

4,102

5,238

5,209

5,319

5,131

4,587

4,142

3,623

3,110

2,484

2,457

2,201

2,273

2,767

2,948

3,353

3,483

3,507

3,523

3,518

3,698

3,570

3,546

3,689

3,839

4,676

6,536

7,417

7,885

7,476

6,362

0

0

0

Depreciation and amortization

2,551

2,366

2,250

2,073

1,768

1,497

1,303

1,167

1,151

1,121

1,050

1,124

1,583

2,078

2,027

1,802

1,184

565

524

529

533

545

584

621

806

939

1,035

1,147

1,129

1,324

1,548

1,777

2,002

2,066

0

0

0

Gain on sale of fixed assets

-

-

-

-

-

-

-

-

-

-

-

0

199

-

292

303

116

2

236

165

151

110

-543

-536

-172

-204

848

803

159

327

-307

-217

93

0

0

0

0

Paid in-kind interest

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

261

271

279

304

310

302

304

262

249

247

210

160

99

38

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-11

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration liability

-284

916

1,416

-6,084

-5,700

-5,800

-6,600

2,100

1,500

2,600

-2,700

-2,800

-2,900

-4,600

2,100

1,300

1,500

1,600

1,000

1,700

1,300

1,500

1,200

700

300

-200

0

0

0

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable

1,254

12,176

357

6,724

1,423

-204

3,166

1,092

1,384

-892

-1,326

-846

-241

1,322

2,408

4,735

2,254

3,415

37,428

-5,481

-4,875

-2,770

-49,142

-8,447

-7,454

-4,114

11,274

11,745

9,936

5,421

-609

-4,523

-1,439

-767

0

0

0

Other current assets

1,483

2,898

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-1,204

-

-2,083

-2,026

-1,504

-1,314

-2,314

2,861

3,101

3,058

6,328

455

986

572

-3,636

-1,148

-1,681

-336

2,039

1,672

1,202

754

-140

-1,644

-423

-882

0

0

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

469

469

469

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-1,050

0

0

0

Other assets

1,895

2,035

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

2,302

808

48

-278

-1,025

-2,906

-462

-575

620

2,779

0

67

-511

243

-1,228

421

914

-202

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) increase in deferred revenue - long term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accrued expenses

-1,285

2,612

4,877

7,532

1,650

1,009

-2,416

-4,633

-4,840

-6,274

-2,649

2,018

3,002

6,581

4,391

5,363

4,176

2,354

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

(Increase) in other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

136

-1,723

-3,857

-1,956

-3,411

-851

911

-691

-395

-2,060

-3,736

-3,352

0

0

0

Other current liabilities

279

80

0

0

0

-

-

-

-

-

-

-284

-99

-158

-219

66

-119

-60

0

0

0

-

-

-

-

-2,069

1,236

1,289

1,609

2,069

0

0

0

-

-

-

-

(Decrease) in deferred revenue - long term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-162

-204

-204

109

162

0

0

0

Other liabilities

-559

-499

-296

-96

104

291

299

306

315

323

761

1,229

395

343

-219

-779

-39

-80

-38

-26

-14

-3

-3

-3

-169

-164

-124

-84

119

-419

0

0

0

-

-

-

-

Net cash used in operating activities

-63,786

-74,698

-64,781

-60,263

-51,015

-46,752

-50,965

-53,927

-55,617

-54,107

-48,723

5,654

14,739

19,518

16,771

-31,749

-37,222

-40,137

1,965

11,813

12,159

13,726

-27,587

-36,624

-39,871

-36,107

-32,140

-30,018

-26,401

-34,644

-37,315

-35,862

-34,900

18,387

0

0

0

Cash flows from investing activities:
Acquisition of AZEDRA manufacturing assets

-

8,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in acquisition of subsidiary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,888

1,888

1,888

1,888

0

0

0

0

-

-

-

-

Purchases of property and equipment

10,293

7,231

4,687

2,142

1,292

817

601

531

140

269

1,288

1,791

3,824

4,286

3,357

2,872

924

370

661

879

757

714

387

158

112

137

85

83

284

767

843

865

715

226

0

0

0

Proceeds from sale of fixed assets

-

-

-

-

-

-

-

-

-

37

43

70

266

347

343

345

159

48

61

84

99

143

149

146

134

174

175

231

352

390

0

0

0

-

-

-

-

Net cash used in investing activities

-10,570

-15,508

-12,964

-10,419

-9,292

-817

-601

-531

-135

-232

-1,245

-1,721

-3,558

-3,939

-9,216

-8,729

-6,967

-6,524

1,800

1,605

1,742

1,829

-238

-12

1,022

3,025

3,078

3,136

2,056

-277

-275

-302

-191

74

0

0

0

Cash flows from financing activities:
Net proceeds common stock

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

37,459

37,458

42,694

77,533

40,078

0

0

0

-

-

-

-

-

-

-

-

Repayment of debt

6,488

5,843

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity issuance costs in connection with acquisition of subsidiary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-45

-45

-45

-45

0

0

0

0

-

-

-

-

Proceeds from exercise of stock options

0

-

-

-

-

-

-

-

-

469

1,300

1,740

1,572

1,340

1,232

1,632

1,676

1,737

1,443

544

489

428

0

68

68

71

181

137

227

306

688

1,579

2,536

3,726

0

0

0

Proceeds from sales of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from redemption of auction rate securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,100

1,100

1,100

100

100

200

300

400

300

0

0

0

Net cash used in financing activities

-4,384

-3,901

-4,589

69,758

84,156

94,717

101,758

27,582

14,802

5,510

49,603

50,175

49,854

49,622

940

1,340

1,384

1,445

1,443

544

493

37,887

37,458

42,762

77,601

40,104

63,563

58,283

23,530

23,654

688

1,579

2,536

3,726

0

0

0

Effect of currency rate changes on cash, cash equivalents and restricted cash

-203

-48

-226

3

-121

-92

-96

-70

41

83

63

16

-94

-86

-39

-25

50

17

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents, and restricted cash

-78,943

-94,155

-82,560

-921

23,728

47,056

50,096

-26,946

-40,909

-48,746

-302

54,124

60,941

65,115

8,456

-39,163

-42,755

-45,199

5,208

13,962

14,394

53,442

9,633

6,126

38,752

7,022

34,501

31,401

-815

-11,267

-36,902

-34,585

-32,555

22,187

0

0

0

Supplemental disclosure of cash flow information
Cash paid for interest

3,993

4,131

4,271

4,410

4,532

4,660

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash financing activity
Subscription receivable

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-